Neurostimulation device company BlueWind Medical has appointed its chairman of the board Daniel Lemaitre as its new CEO, effective last week on Jan. 1.
Lemaitre has served as BlueWind Medical’s chairman of the board since November 2018. He’s also a board member of Globus Medical as well as chairman of Endologix.
The industry veteran was CEO at Medtronic (NYSE:MDT)-acquired CoreValve after he was Medtronic’s senior VP of strategy and business development. Lemaitre also worked as a medical device analyst at Cowen & Company and at Merrill Lynch early in his career.
Lemaitre is taking over for BlueWind’s former CEO Guri Oron, who, after six years in the role, will take on the position of president & GM.
“BlueWind has the potential to revolutionize the treatment of OAB which impairs the quality of life of millions of patients in the US and around the world,” Lemaitre said in a news release. “Our RENOVA device, is easy to implant, potentially devoid of severe complications and is in a form factor that works for physicians and patients alike. With our technology and a spectacular team, we expect to help many patients with our technology that heretofore were not adequately treated with conservative or more invasive technologies.”
“Dan is assuming the role of CEO at a critical time for the company and for the [over-active bladder] market,” added Ilan Neugarten, chairman of the board at Rainbow Medical, BlueWind’s largest investor. “With his tremendous experience, Dan will help transform BlueWind from a technology stage company to a leading player in the neuromodulation market.”
“We are excited about the potential for our technology and are looking forward to a successful journey with Dan’s leadership as we embark on our pivotal study at sites in Europe and the U.S.,” Oron said.
BlueWind Medical is developing miniature, wireless neurostimulators that can either be injected or implanted in a minimally invasive procedure to treat multiple indications. The company’s Renova neursostimulation system has CE Mark approval but is not cleared for marketing in the U.S.